{4-methyl-2,6,7-trioxabicyclo[2.2.2]octan-1-yl}methanol | 89995-22-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: {4-methyl-2,6,7-trioxabicyclo[2.2.2]octan-1-yl}methanol
• 英文别名: (4-Methyl-2,6,7-trioxabicyclo[2.2.2]octan-1-yl)methanol；(4-methyl-2,6,7-trioxabicyclo[2.2.2]octan-1-yl)methanol
• CAS: 89995-22-2
• 化学式: C₇H₁₂O₄
• 分子量: 160.17
• InChiKey: UBMGXCFGIZVQES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  47.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  {4-methyl-2,6,7-trioxabicyclo[2.2.2]octan-1-yl}methyl acetate 在 sodium hydride 作用下， 以 甲醇 、 mineral oil 为溶剂， 以85 %的产率得到{4-methyl-2,6,7-trioxabicyclo[2.2.2]octan-1-yl}methanol
  参考文献：
  名称：

  [EN] PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS
  [FR] DÉRIVÉS D'AMINO PYRIDAZINYLE EN TANT QU'INHIBITEURS D'ALK5

  摘要：

  The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.

  公开号：

  WO2023046698A1

文献信息

• Polymer Derivatives Comprising an Acetal or Ketal Branching Point
  申请人：Nektar Therapeutics

  公开号：US20140039167A1

  公开（公告）日：2014-02-06

  The invention conjugates that can be prepared by contacting a polymer comprising an acetal or ketal branching point with a pharmacologically active agent under conditions suitable to form a covalent attachment between the polymer and the pharmacologically active agent.
• US8562965B2
  申请人：——

  公开号：US8562965B2

  公开（公告）日：2013-10-22
• US9308273B2
  申请人：——

  公开号：US9308273B2

  公开（公告）日：2016-04-12
• [EN] PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS<br/>[FR] DÉRIVÉS D'AMINO PYRIDAZINYLE EN TANT QU'INHIBITEURS D'ALK5
  申请人：[en]CHIESI FARMACEUTICI S.P.A.

  公开号：WO2023046698A1

  公开（公告）日：2023-03-30

  The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.